World Journal of Surgery

, Volume 28, Issue 9, pp 896–903 | Cite as

Andrenocortical Carcinomas: Twelve-year Prospective Experience

  • Libuse Tauchmanovà
  • Annamaria Colao
  • Luigi Antonio Marzano
  • Lucianna Sparano
  • Luigi Camera
  • Annalisa Rossi
  • Giovanna Palmieri
  • Ettore Marzano
  • Marco Salvatore
  • Guido Pettinato
  • Gaetano Lombardi
  • Riccardo Rossi
Original Scientific Reports


Adrenocortical carcinoma (AC) is a rare tumor with poor prognosis. Twenty-two patients (14 F, 8 M; age 22 to 59 years; median, 43 years) with AC were evaluated prospectively in a single center: tumor stage was I–II in 12 cases and III–IV in 10. The overall survival in our cohort was 41.6 ± 42 months; 16 subjects are still alive. Curative surgery was followed by longer survival than debulking or no surgery (p < 0.0001). The first relapse was highly predictive for further recurrences. Recurrent ACs were progressively more aggressive, and they occurred with variable but ever shorter intervals. At diagnosis, 14 patients (63.5%) presented with features of clear adrenocortical hyperactivity. Despite the absence of clinical signs of hormonal excess, all other patients presented some abnormalities of steroid secretion. The most common clinical finding was a recent diagnosis of moderate-to-severe hypertension (68%), poorly controlled by pharmacological treatment, often associated with multiple cardiovascular risk factors. High mitotic rate and undifferentiated polymorph cellular pattern were associated with worse prognosis. Response to treatments other than surgery (mitotane chemotherapy) was better in patients treated early after the first surgery. In conclusion, curative surgery was the most effective treatment. Monitoring arterial pressure, endocrine parameters, and metabolic parameters can be helpful for the early detection of AC recurrences.


  1. 1.
    Hanna, NH, Kenady, E 2000Advances in the management of adrenal tumoursCurr. Opin. Oncol.114953CrossRefGoogle Scholar
  2. 2.
    Thompson, NW, Cheung, PSY 1987Diagnosis and treatment of functioning and nonfunctioning adrenocortical neoplasms including incidentalomasSurg. Clin. North Am.67423436PubMedGoogle Scholar
  3. 3.
    Søreide, JA, Brabrand, K, Thoresen, Sø 1992Adrenal cortical carcinoma in Norway, 1970-1984World J. Surg.16663668PubMedGoogle Scholar
  4. 4.
    McFarlane, DA 1958Cancer of the adrenal cortex: The natural history, prognosis and treatment in a study of fifty-five casesAnn. R. Coll. Surg. Engl.23155PubMedGoogle Scholar
  5. 5.
    Luton, JP, Cerdas, S, Billaud, L,  et al. 1990Clinical features of adrenocortical carinoma, prognostic factors, and the effects of mitotane therapyN. Engl. J. Med.32211951201PubMedGoogle Scholar
  6. 6.
    Henley, DJ, Heerden, JA, Grant, CS,  et al. 1983Adrenal cortical carcinoma: a continuing challengeSurgery94926931PubMedGoogle Scholar
  7. 7.
    Decker, RA, Kuehner, ME 1991Adrenocortical carcinomaAm. Surg.57502513PubMedGoogle Scholar
  8. 8.
    Icard, P, Goudet, P, Charpenay, C,  et al. 2001Adrenocortical carcinomas: surgical trends and results of a 253 patient series from the French Association of Endocrine Surgeons study groupWorld J. Surg.25891897CrossRefPubMedGoogle Scholar
  9. 9.
    Vassilopoulou-Sellin, R, Schultz, PN 2001Adrenocortical carcinoma. Clinical outcome at the end of the 20th centuryCancer9211131121CrossRefPubMedGoogle Scholar
  10. 10.
    Mantero, F, Terzolo, M, Arnaldi, G,  et al. 2000Survey on adrenal incidentaloma in ItalyJ. Clin. Endocrinol. Metab.85637644CrossRefPubMedGoogle Scholar
  11. 11.
    Zarrilli, L, Marzano, LA, Tauchmanovà, L,  et al. 1999Incidentalomi surrenalici: risultato di uno studio prospettico di 100 casi. Focus – La chirurgia dei surreni oggi. Ospedali d’ItaliaChirurgia (Bucur).5655659Google Scholar
  12. 12.
    Wajchenberg, BL, Albergaria-Pereira, MA,  et al. 2000Adrenocortical carcinoma: clinical and laboratory observationCancer88711736CrossRefPubMedGoogle Scholar
  13. 13.
    Bertagna, Ch, Orth, DN 1981Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978)Review. Am J Med71855875CrossRefGoogle Scholar
  14. 14.
    Chrousos, G 1999Recent advances in diagnostic and therapeutic strategies.. In Bornstein SR, moderator, Adrenocortical tumors: recent advances in basic concepts and clinical managementAnn. Intern. Med.30764771Google Scholar
  15. 15.
    Latronico, AC, Chrousos, GP 1997Extensive personal experience: adrenocortical tumorsJ. Clin. Endocrinol. Metab.8213171324CrossRefPubMedGoogle Scholar
  16. 16.
    Stojadinovic, A, Ghossein, RA, Hoos, A,  et al. 2002Adrenocortical carcinoma: clinical, morphologic, and molecular characterizationJ. Clin. Oncol.20941950CrossRefPubMedGoogle Scholar
  17. 17.
    Sasano, H, Suzuki, T, Moriya, T 2001Discerning malignancy in resected adrenocortical neoplasmsEndocr. Pathol.12397406CrossRefPubMedGoogle Scholar
  18. 18.
    Hutter, AM,Jr, Kayhoe, DE 1966Adrenal cortical carcinoma: clinical features in 138 patientsAm. J. Med.41572580CrossRefPubMedGoogle Scholar
  19. 19.
    Sullivan, M, Boileau, M, Hodges, CV 1978Adrenal cortical carcinomaJ. Urol.120660665PubMedGoogle Scholar
  20. 20.
    Weiss, LM 1984Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumorsAm. J. Surg. Pathol.8163169PubMedGoogle Scholar
  21. 21.
    Weiss, LM, Medeiros, LJ, Vickety, AL,Jr 1989Pathologic features of prognostic significance in adrenocortical carcinomaAm. J. Surg. Pathol.13202206PubMedGoogle Scholar
  22. 22.
    Rossi, R, Tauchmanovà, L, Luciano, A,  et al. 2000Subclinical Cushing’s syndrome in patients with adrenal incidentaloma. Clinical and biochemical featuresJ. Clin. Endocrinol. Metab.8514401448CrossRefPubMedGoogle Scholar
  23. 23.
    Rosai, J 1996

    Adrenal gland and other paraganglia

    Rosai, R eds. Ackerman’s surgical pathologyvol 1, 8th editionMosbySt. Louis
    Google Scholar
  24. 24.
    Kasperlik-Zaluska, A, Migdalska, BM, Zglicznski, S,  et al. 1995Adrenocortical carcinoma. A clinical study and treatment result of 52 patientsCancer7525872591PubMedGoogle Scholar
  25. 25.
    Wooten, MD, King, DK 1993Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literatureCancer7231453155PubMedGoogle Scholar
  26. 26.
    McKenna, TJ, Miller, RB, Liddle, GW 1977Plasma pregnenolone and 17-OH-pregnenolone in patients with adrenal tumors, ACTH excess or idiopathic hirsutismJ. Clin. Endocrinol. Metab.44231234PubMedGoogle Scholar
  27. 27.
    Medonca, BB, Lucon, AM, Menezes, CA,  et al. 1995Clinical, hormonal and pathological findings in a comparative study of adrenal cortical neoplasms in childhood and adulthoodJ. Urol.15420042009CrossRefPubMedGoogle Scholar
  28. 28.
    Kaye, TB, Crapo, L 1990The Cushing’s syndrome: an update on diagnostic testsAnn. Intern. Med.112434444PubMedGoogle Scholar
  29. 29.
    Reincke, M, Nieke, J, Krestin, GP,  et al. 1992Preclinical Cushing’s syndrome in adrenal “incidentalomas”: comparison with adrenal Cushing’s syndromeJ. Clin. Endocrinol. Metab.75826832CrossRefPubMedGoogle Scholar
  30. 30.
    Ambrosi, B, Sartorio, A, Pizzocaro, A,  et al. 2000Evaluation of haemostatic and fibrinolytic markers in patients with Cushing’s syndrome and in patients with adrenal incidentalomaExp. Clin. Endocrinol. Diabetes108294298CrossRefPubMedGoogle Scholar
  31. 31.
    Barzon, L, Zucchetta, P, Boscaro, M,  et al. 2001Scintigraphic pattern of adrenocortical carcinoma: morpho-functional correlatesEur. J. Endocrinol.145743748PubMedGoogle Scholar
  32. 32.
    Pommier, RF, Brennan, MF 1992An eleven-year experience with adrenocortical carcinomaSurgery112963970PubMedGoogle Scholar
  33. 33.
    Haak, HR, Hermans, J, Velde, CJ,  et al. 1994Optimal treatment of adrenocortical carcinoma with mitotane : results in a consecutive series of 96 patientsBr. J. Cancer69947951PubMedGoogle Scholar
  34. 34.
    Khoram-Manesh, A, Ahlman, H, Jansson, S,  et al. 1998Adrenocortical carcinoma: surgery and mitotane for treatment and steroid profiles for follow-upWorld J. Surg.2605611CrossRefGoogle Scholar
  35. 35.
    Terzolo, M, Anna-Pia, A, Berruti, A,  et al. 2000Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancerJ. Clin. Endocrinol. Metab.8522342238CrossRefPubMedGoogle Scholar
  36. 36.
    Schteingart, DE 1992Treating adrenal cancerEndocrinologist2149157Google Scholar
  37. 37.
    Bates, SE, Shieh, CY, Mickley, LA,  et al. 1991Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/p-glycoprotein) which is also expressed by adrenocortical carcinomasJ. Clin. Endocrinol. Metab.731829PubMedGoogle Scholar
  38. 38.
    Ahlman, H, Khorram-Manesh, A, Jansson, S,  et al. 2001Cytotoxic treatment of adrenocortical carcinomaWorld J. Surg.25927933CrossRefPubMedGoogle Scholar
  39. 39.
    Hogan, TF, Gilchrist, KW, Westring, DW,  et al. 1980A clinical and pathological study of adrenocortical carcinoma: therapeutic implicationsCancer4528802883PubMedGoogle Scholar
  40. 40.
    Wachenfeld, C, Beuschlein, F, Zwermann, O,  et al. 2001Discerning malignancy in adrenocortical tumors: are molecular markers useful?Eur. J. Endocrinol.145335341PubMedGoogle Scholar
  41. 41.
    Wajchenberg, BL, Pereira, MA, Medonca, BB,  et al. 2000Adrenocortical carcinoma. Clinical and laboratory observationsCancer88711736CrossRefPubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2004

Authors and Affiliations

  • Libuse Tauchmanovà
    • 1
  • Annamaria Colao
    • 1
  • Luigi Antonio Marzano
    • 2
  • Lucianna Sparano
    • 3
  • Luigi Camera
    • 4
  • Annalisa Rossi
    • 1
  • Giovanna Palmieri
    • 1
  • Ettore Marzano
    • 2
  • Marco Salvatore
    • 4
  • Guido Pettinato
    • 3
  • Gaetano Lombardi
    • 1
  • Riccardo Rossi
    • 1
  1. 1.Department of Molecular and Clinical Endocrinology and Oncology“Federico II” University of NaplesNaplesItaly
  2. 2.Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrine and General Surgery,“Federico II” University of NaplesNaplesItaly
  3. 3.Department of Anatomical Pathology and Cytology“Federico II” University of NaplesNaplesItaly
  4. 4.Department of Biomorphological and Functional Sciences“Federico II” University of NaplesNaplesItaly

Personalised recommendations